כניסה 
עקבו אחרינו בפייסבוק אנברל - Enbrel
מתוך ויקירפואה
| אנברל - Enbrel | ||
|---|---|---|
| מרכיב פעיל | ETANERCEPT | |
| קבוצה פרמקולוגית (ATC) | "SELECTIVE IMMUNOSUPPRESSIVE AGENTS" | |
| שם התרופה | "אנברל®" (קישור לדף התרופה במאגר משרד הבריאות) |
|
| סל הבריאות | כלול | |
| מסגרת הכללה בסל | תרופה מוגבלת לרישום ע"י רופא מומחה או הגבלה אחרת.
1. התרופה תינתן לטיפול בחולה הסובל מאחד מאלה:
2. התרופה תינתן על פי מרשם של רופא מומחה בדרמטולוגיה. 3. הטיפול בתרופה לחולה העונה על תנאי פסקה (1) (א), יינתן בהתקיים כל אלה:
|
|
התוויות |
*Rheumatoid arthritis: Enbrel is indicated for the treatment of active rhematoid arthritis in adults when the response to disease-modifying antirheumatic drugs (DMARDs) including methotrexate (unless contraindicated) has been inadequate. Enbrel can be used in combination with methotrexate in patients who do not respond adequately to methotrexate alone. Reducing signs and symptoms and inhibiting the progression of structural damage in patients with moderately to severely active rheumatoid arthritis. Enbrel, alone or in combination with methotrexate, has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function. *Polyarticular juvenile idiopathic arthritis: Enbrel is indicated for the treatment of active polyarticular-course juvenile chronic arthritis in chilldren aged 4 to 17 years who have had an inadequate response to or who have proved intolerant of methotrexate. Enbrel has not been studied in children aged less than 4 years. *Psoriatic arthritis : Treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying antirheumatic drug therapy has been inadequate. Enbrel has been shown to improve physical function in patients with psoriatic arthritis, and to reduce the rate of progression of peripheral joint damage as measured by X ray in patients with polyarticular symmetrical subtypes of the disease. *Ankylosing spondylitis: Treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy. *Plaque psoriasis: Treatment of adults patients (18 years or older) with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. *Paediatric plaque psoriasis: Treatment of chronic severe plaque psoriasis in children and adolescents from the age of 8 years who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies
| |
| שם יצרן | WYETH PHARMACEUTICALS LIMITED, U.K. | |
| שם בעל הרישום | NEOPHARM LTD | |
| עלון לרופא | "עלון לרופא באנגלית" | |
| עלון לצרכן | "עלון לצרכן בעברית,אנגלית וערבית" | |